Oncology is the largest component of the imaging business, with over 50% of our engagements in the full array of oncology indications. Our structure and breadth of capabilities are aligned to adjust and scale our imaging services to your needs. We have the specific expertise and flexibility that you expect from an imaging partner for early phase or exploratory imaging studies, as well as the rigor and throughput for large late phase submission trials.

Our in-house physician team includes experts in radiology, oncology, nuclear medicine; PhDs with imaging background, scientists with expansive trial experience, technologists (MRI, PET, and CT) who are ready to support your protocol and your study’s imaging needs. Partnering with PAREXEL also brings you access to our worldwide network of reviewers including over 300 sub-specialized radiologists and oncologists.

Article

The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. Read More..

Medical Imaging: Valuable for Clinical Trials

Brochure

Medical imaging is a powerful and cost-effective tool for accelerating the drug development process. The use of medical imaging as a surrogate endpoint allows sponsors to “see” the effect of a new drug at a much earlier stage of research, compared to traditional endpoints such as clinical benefit or survival times. Read More..

Factsheet

Explore

All Solutions

All Solutions

Clinical Research

Informatics

Consulting

View More...

Early Phase Services

More of What You Need for a Stronger Start in Phase I. Your journey from new molecule to new medicine starts with appropriate subjects, world class facilities, and more timely results. PAREXEL® provides comprehensive early phase testing services through our own hospital-based clinical units on three continents.

Phase II-III Services

Improving Your Journey by Improving Every Step of Your Clinical Trials.
During the part of your journey from Proof-of-Concept through regulatory submission, PAREXEL® Phase II-III specialists optimize every step of your clinical trials by every means possible.

Perceptive MyTrials®

Single-Point Access to Both Data and Applications to Simplify Your Journey
When your journey heads into clinical trials, accessing data, information, and all the applications you need from a single place saves untold time and agitation. That’s what Perceptive MyTrials from PAREXEL® does.

Electronic Data Capture

The DataLabs® EDC (Electronic Data Capture) solution is uniquely focused on simplifying workflows and delivering superior user experiences. Its advanced EDC features help streamline the entire process starting from study design all the way to collection, management and reporting of clinical trial data.

Electronic Clinical Outcome Assessments (eCOA)

Clinical Outcome Assessments (COAs) measure a patient’s symptoms, overall mental state, or the effects of a disease or condition on how the patient functions. COAs can be used to determine whether or not a drug has been demonstrated to provide treatment benefit. COA types include ePRO (electronic Patient Reported Outcomes).

The 2014 Lugano Classification - Using the New “Cheson” Criteria in Lymphoma Clinical Trials

Learn about RECIST

RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published rules that define when cancer patients improve ("respond"), stay the same ("stable") or worsen ("progression") during treatments.